Earlier this year, Canada became the first major market in the world where generic forms of semaglutide became legal. The competition was on: Manufacturers raced to secure Health Canada approval so ...

The generic versions will give patients and healthcare providers access to “affordable alternatives" to brand name formats, says Canadian drug manufacturer, Apotex You can save this article by ...

Telehealth provider Hims & Hers Health Inc. announced Thursday the availability of generic semaglutide through its platform, allowing eligible Canadians access to digital prescriptions for the popular ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Some Canadian ...

Two generic versions of Ozempic are set to start arriving in Canadian pharmacies this week, which means patients who use the drug to treat diabetes or for weight loss may have more options for a ...

The Trump administration on Monday said it is adding generic medications to its direct-to-consumer drug sales website, TrumpRx. The platform, which launched in February, is key to his administration's ...

India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? Limited time: Save 25% on NBC News subscription Get ...

Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Health Canada ‌ ...

Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established cardiovascular disease or multiple risk factors, and to improve glycemic control ...

A report from Sen. Maggie Hassan, D-N.H., describes how GSK avoided paying $385 million in Medicaid rebates and retained its monopoly of the market for asthma inhaler Flovent. (Photo by Cristina Arias ...